anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

158,581-158,640 of 319,975

filter-aware
08
The slide uses a consistent visual language of bar charts with trend lines to communicate growth.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide uses a three-column layout to frame the problem, the current solution/progress, and the strategic approach.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
The slide uses a three-column layout to present market data and strategic initiatives.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
11
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
12
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
13
The slide lists 6 points (5R + digital), though the title refers to the 5R framework.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
14
The slide uses a stacked bar chart to compare AstraZeneca (first bar) against five competitors (R, P, N, J, M).AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
15
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
16
The slide outlines a multi-stage R&D process involving data integration, AI analysis, and biological validation.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Loop · Hypothesis Test1 hit
17
The slide uses a grid-based categorization of drug modalities.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Loop · Hypothesis Test1 hit
18
The slide uses a three-column layout to present project metrics, chemical safety improvements, and biological efficacy results.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Loop · Hypothesis Test1 hit
19
The slide uses a combination of process flow, microscopy imagery, and a bar chart to demonstrate the therapeutic potential of HVP cells.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Loop · Hypothesis Test1 hit
20
The central cycle diagram illustrates the efficiency gains (1 vs 3 years, 1000 vs 2500 compounds).AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Loop · Hypothesis Test1 hit
21
The slide uses a four-column layout to present distinct technological approaches to clinical trial optimization.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Loop · Hypothesis Test1 hit
22
The slide uses a process flow at the top and a four-pillar framework at the bottom to explain the trial's methodology.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Loop · Hypothesis Test1 hit
23
The slide uses a color-coded grid to distinguish between highlighted pipeline assets and others, with extensive footnotes detailing specific drug mechanisms and disease targets.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
24
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
25
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
26
The slide uses a Gantt-style chart to visualize the compression of development phases.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
27
The slide uses a comparison structure between clinical trial data and real-world evidence.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
28
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
29
The slide uses a three-column layout to present product features, scientific data, and clinical trial status.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
30
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
31
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
32
The slide acts as a logistical guide for a multi-session virtual event.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
33
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
34
CVRM stands for Cardiovascular, Renal and Metabolism.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
35
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
36
The slide uses a four-column layout to map disease areas to specific patient outcomes, prevalence data, and therapeutic candidates.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Beat · Market Size1 hit
37
Phase I SAD data presented with dose-response curves for 20mg, 30mg, 60mg, 90mg, and 120mg cohorts.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Beat · Market Size1 hit
38
Slide presents data from PROMIS observational trial and SATELLITE Phase IIa trial.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Beat · Market Size1 hit
39
The slide uses a three-panel structure to compare preclinical rodent models (left/center) with clinical trial data (right).AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Beat · Market Size1 hit
40
The slide combines a biological mechanism diagram with two bar charts showing clinical efficacy data.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Beat · Market Size1 hit
41
The slide uses color coding to distinguish between highlighted medicines and others in the pipeline.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations Beat · Market Size1 hit
42
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
43
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
44
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
45
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
46
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
47
Includes event date, speaker names/titles, and registration link.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
48
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
49
The slide uses a timeline framework to demonstrate clinical efficacy over time.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
50
The chart shows revenue split between US and Ex-US markets.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
51
Includes references to specific clinical stages and therapeutic approaches (Farxiga, Lokelma, roxadustat).AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
52
Slide 6 of a presentation. Combines patient demographics, clinical trial results (DIALIZE), and revenue growth.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
53
Includes footnotes for clinical trial abbreviations and data sources.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
54
The slide uses a process-oriented layout to map drug development stages to a timeline of upcoming news events.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
55
Includes a screenshot of a meeting interface toolbar.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
56
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
57
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
58
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
59
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
60
Includes speaker names and titles, date, and webinar registration link.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
61
AstraZeneca | Investor Day Presentation Deck | 86 slidesAstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
62
The slide uses a three-column layout to present quantitative data points for each disease category, supported by footnotes.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
63
The slide uses a three-column layout to categorize strategic focus areas.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
64
The slide uses a combination of a biological pathway diagram and a violin plot to demonstrate drug efficacy.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
65
Includes longitudinal pharmacodynamic data for IL5 and IL13 reduction and a list of Phase II trials with patient counts and timelines.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
66
The slide uses a combination of line charts and bar charts to demonstrate efficacy, alongside a molecular pathway diagram.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit
67
Includes line chart for pain scores over time, forest plot for NGF suppression efficacy, and trial status list.AstraZeneca | Investor Day Presentation Deck | 86 slides · AstraZeneca
Conference presentation Investor relations 1 hit